1. Introduction
bone loss, stroke, fracture, Accelerated loss of bone mineral, chronic disease
OSTEOPOROTIC FRACTURE, MYOCARDIAL INFARCTION, BONE LOSS, BREAST CANCER, STROKE, FRACTURE DUE TO OSTEOPOROSIS, ESTROGEN DEFICIENCY, ESTROGEN DEFICIENCY, OSTEOPOROSIS, CHRONIC DISEASE
Estrogen deficiency is a major cause of loss of postmenopausal bone mineral density (BMD). This study aimed to evaluate the effects of equol and resveratrol on bone turnover biomarkers in postmenopausal women. Sixty healthy postmenopausal women were randomly assigned to receive 200 mg fermented soy containing 10 mg equol and 25 mg resveratrol or a placebo for 12 months. Whole-body BMD and bone turnover biomarkers, such as deoxypyridinoline (DPD), tartrate-resistant acid phosphatase 5b (TRACP-5b), osteocalcin, and bone-specific alkaline phosphatase (BAP), were measured at baseline and after 12 months of treatment. At the end of treatment, DPD, osteocalcin, and BAP significantly improved in the active group (The prevalence of age-related bone loss is higher in women than in men, especially postmenopausal women. This loss is typically associated with osteoporosis, a common chronic disease responsible for reduced bone strength, disruption of bone architecture, and an increased risk of fracture. In postmenopausal women, the incidence of hospitalization due to osteoporotic fractures is higher than that of stroke, myocardial infarction, and breast cancer. After the age of 50 years, approximately 50% of women have at least one fracture due to osteoporosis [Accelerated loss of bone mineral density (BMD), which occurs during menopause due to estrogen deficiency, is a key contributor to the incidence of osteoporotic fractures [Recently, significant advances have been made in the development of nutraceutical agents to prevent age-related bone loss. Phytoestrogens are a group of plant polyphenols that are commonly used for the treatment of menopause-related conditions. They can be classified into four classes: isoflavones, lignans, coumestans, and stilbenes. The estrogenic activity of these compounds may exert a multitude of benefits in estrogen-deficient menopausal women, including beneficial effects on osteoporotic bone loss [This randomized, placebo-controlled trial evaluated the efficacy of the combined use of resveratrol and equol on bone turnover biomarkers and whole-body BMD in postmenopausal women.